Year archive

Lytix Biopharma AS — 2026 filings

All 37 regulatory filings released by Lytix Biopharma AS (LYTIX) in 2026, sourced directly from the official regulator.

37 Filings

2026 Period

2026 filings (37)

Filing	Released	Lang
Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances - Attachment: 2026-Q1 - Lytix Biopharma - Quarterly Presentation - Final.pdf Investor Presentation	2026-05-21	English
Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances Earnings Release Q1 2026	2026-05-21	English
Lytix Biopharma: Invitation to the Q1 2026 Results Presentation Report Publication Announcement	2026-05-15	English
New Phase II Study Data from Lytix Biopharma’s Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma Regulatory Filings	2026-05-06	Norwegian
Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026 Regulatory Filings	2026-04-21	English
Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma - Attachment: Lytix_AACR Poster_Fin Regulatory Filings	2026-04-21	English
Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma Regulatory Filings	2026-04-21	English
Lytix Biopharma ASA – Conversion to public limited liability company and name change registered Regulatory Filings	2026-04-16	English
Lytix Biopharma AS: Minutes from Annual General Meeting - Attachment: Lytix Biopharma - Minutes from Annual General Meeting 2026-04-14 - Signed.pdf AGM Information	2026-04-14	Norwegian
Lytix Biopharma AS: Minutes from Annual General Meeting AGM Information	2026-04-14	English
Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS - Attachment: Notification of Trade - DDH.pdf Director's Dealing	2026-04-09	English
Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS Director's Dealing	2026-04-09	English
Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of Growth - Attachment: Lytix Biopharma - Appoints COO Renee Amundsen - 2026-04-07.pdf Board/Management Information	2026-04-07	English
Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of Growth Board/Management Information	2026-04-07	English
Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026 - Attachment: Lytix Biopharma - Notice to The Annual General Meeting 2026 Final.pdf AGM Information	2026-03-25	English
Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026 Proxy Solicitation & Information Statement	2026-03-25	English
Lytix Biopharma AS: Annual Report for 2025 - Attachment: 2025 Lytix - Annual Report - Final 2023-03-23.pdf Annual Report FY 2025	2026-03-24	English
Lytix Biopharma AS: Annual Report for 2025 Report Publication Announcement	2026-03-24	English
Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026 Regulatory Filings	2026-03-18	English
Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC) Regulatory Filings	2026-02-17	English
Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report - Attachment: 2025-Q4 - Lytix Biopharma - Quarterly Presentation - 2025-12-31 - Final.pdf Investor Presentation	2026-02-12	English
Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report - Attachment: 2025-H2 - Lytix Biopharma - Interim Report - IFRS - 2025-12-31 - Final.pdf Interim / Quarterly Report Q4 2025	2026-02-12	English
Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report Report Publication Announcement Q4 2025	2026-02-12	English
Lytix Biopharma AS – Last day of the Subscription Period in the Subsequent Offering Capital/Financing Update	2026-02-10	English
Lytix Biopharma: Invitation to Q4 2025 Results Presentation and Publication of H2 2025 Report Report Publication Announcement	2026-02-05	English
Lytix Biopharma AS – Publication of Prospectus regarding Subsequent Offering and commencement of Subscription Period Capital/Financing Update	2026-01-27	English
Lytix Biopharma AS – EGM minutes - Subsequent Offering, ASA Conversion, Board Expansion and Board Authorization Approved - Attachment: Lytix - EGM minutes 2026-01-26 - Final - Signed.pdf AGM Information	2026-01-26	Norwegian
Lytix Biopharma AS – EGM minutes - Subsequent Offering, ASA Conversion, Board Expansion and Board Authorization Approved Declaration of Voting Results & Voting Rights Announcements	2026-01-26	English
Lytix Biopharma AS - New share capital registered Share Issue/Capital Change	2026-01-14	English
Lytix Biopharma AS – Notice of extraordinary general meeting 26 January 2026 - Attachment: Lytix - EGM notice inc appendices 26.01.2026 Final.pdf Proxy Solicitation & Information Statement	2026-01-12	Norwegian
Lytix Biopharma AS – Notice of extraordinary general meeting 26 January 2026 Share Issue/Capital Change	2026-01-12	English
Lytix Biopharma AS – Mandatory notification of trade by close associate of primary insider - Attachment: Lytix - Saturn Invest AS - Mandatory Notification of trade by primary insiders and close associ Director's Dealing	2026-01-09	English
Lytix Biopharma AS – Mandatory notification of trade by close associate of primary insider Director's Dealing	2026-01-09	English
Lytix Biopharma AS: Key information relating to potential subsequent offering Share Issue/Capital Change	2026-01-09	English
Lytix Biopharma AS: Private placement successfully completed with oversubscription Share Issue/Capital Change	2026-01-09	English
Financial calendar Report Publication Announcement	2026-01-07	English
Finansiell kalender Report Publication Announcement	2026-01-07	Norwegian